Latest Everolimus Stories
-- Overall survival data for Tafinlar® and Mekinist® combination to be presented in metastatic BRAF V600E/K mutation-positive cutaneous melanoma EAST HANOVER, N.J., May 27, 2015 /PRNewswire/
- More Than 100,000 People with Coronary Artery Disease Have Been Treated with Absorb PARIS, May 19, 2015 /PRNewswire/ -- Abbott announced today that it has received CE Mark for
PARIS, May 19, 2015 /PRNewswire/ -- At the late-breaking trials session today at EuroPCR, the official congress of European
Additional Data from EVOLVE II Pivotal Trial Demonstrate Safety and Performance in Patients with Diabetes at One Year MARLBOROUGH, Mass., May 19, 2015 /PRNewswire/ -- Boston Scientific (NYSE:
Study in New England Journal of Medicine Examines Outcomes of Over 18,000 Patients with Coronary Artery Disease NEW YORK, March 16, 2015 /PRNewswire-USNewswire/ -- Newer drug-coated
DALLAS and NEW YORK, March 5, 2015 /PRNewswire/ -- PlasmaTech Biopharmaceuticals, Inc.
- Update on complete remissions with personalized cell therapy CTL019 in patients with relapsed/refractory acute lymphoblastic leukemia EAST HANOVER, N.J., Dec.
EVOLVE II Trial Represents the First Successful U.S. Pivotal Trial of a Bioabsorbable Polymer Stent MARLBOROUGH, Mass., Nov. 19, 2014 /PRNewswire/ -- In the first successful U.S.
First Patient Enrolled in PLATINUM Diversity Trial Evaluating Performance in Women, Black Americans, Latinos/Hispanics, Native Americans and Alaska Natives with Coronary Artery Disease
- Afinitor led to an unprecedented median overall survival of 44 months, which represents a clinically meaningful while not statistically significant improvement(1) EAST HANOVER,
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.